Background: Induction of cancer creates many molecular to physiological changes in the human body. Observation of these variations between normal & diseased conditions become the basis of disease diagnosis. Present study analyzed blood lipid profile, relative to changes in genotype, at the early stage of stomach adenocarcinoma. Materials and Method: Present study was based on establishment of relationship between genotype to phenotype. Genotypic features were collected through RNAseq analysis, which was further mapped with phenotypic expression in the form of blood lipid profile. Results: To observe the significance difference between phenotypic expressions of normal and cancerous condition, gene signatures from multiple sources of studies were mapped with blood lipid profile including: Total Cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, Non-HDL-C, and TG to HDL ratio. Significance difference found between phenotypic expression of normal and cancerous condition. Conclusion: Through multi-signature-based population observation, it was found that blood-lipid density decreases at the early-stage of stomach adenocarcinoma. Further, blood-lipid profile can be used for early disease prediction of stomach adenocarcinoma as well as other cancer types.

The authors have declared no competing interest.

Author Om Prakash is thankful to the Indian Council of Medical Research (ICMR), New Delhi, India for financial support through a Research Associate fellowship (Award letter no. BMI/11(12)/2020, dated: 04/02/2021). The authors utilized research infrastructure at the Institute of Medicinal & Aromatic Plants (CIMAP), Lucknow, India.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data sources (publically available) considered during the study: (1) The Cancer Genome Atlas, The GDC data portal https://portal.gdc.cancer.gov/. (2) Gene Expression Profiling Interactive Analysis database (http://gepia2.cancer-pku.cn/#index). (3) cBioPortal for Cancer Genomics (https://www.cbioportal.org/). (4) Pubmed (https://pubmed.ncbi.nlm.nih.gov/).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript